Viewing nowCombinationGlucitapormin Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.

MFDS item code 202300847 · Approved 2023.03.13 · Insurance code 693202580
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps control blood sugar in patients with type 2 diabetes by using sitagliptin and metformin together. It is effective in improving blood sugar levels in conjunction with diet and exercise therapy. It particularly aids in stable management of blood sugar, supporting diabetes treatment. Therefore, this medication is used to enhance blood sugar control in patients with type 2 diabetes.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Should Not Receive This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient’s blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because of its metformin component (see Precautions for Use, 2. Patients Who Should Not Receive This Medicine).
This medication contains two components that are used in the treatment of diabetes. The first component is a drug that helps to control blood sugar, and serious allergic reactions or side effects such as pancreatitis may rarely occur, so caution is required during the initial dosage. The second component lowers blood sugar and may pose risks for patients with poor kidney function or liver dysfunction, thus consultation with a physician is essential before administration. Furthermore, this medication should not be used in patients with weak kidney function, acute heart conditions, or severe infections, or in pregnant or breastfeeding women. Caution is also required during irregular meals, vigorous exercise, or the use of other medications, as there is a risk of hypoglycemia or other side effects. Common side effects during treatment may include diarrhea, nausea, headache, and upper respiratory infections, with rare occurrences of severe skin reactions, arthralgia, and myalgia. If hypoglycemic symptoms occur during treatment, it is crucial to inform a physician immediately and receive appropriate measures. Specifically, administration of this medication should be temporarily halted before and after surgery and resumed only after kidney function returns to normal. There may be interactions when this medication is taken with other hypoglycemic agents or specific medications, so all concomitant medications should be disclosed to the physician. Elderly patients should undergo regular kidney function tests due to a higher likelihood of decreased kidney function. In case of overdose, immediate medical attention is necessary, and some components can be removed by dialysis. It is advisable to avoid alcohol consumption during the treatment with this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that does not allow air to enter, preferably at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.
Oval film-coated tablet, light pink in color
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.